Clinical trials
Consolidation clinical trials
Below are recruiting consolidation clinical trials, each written for real people, not researchers. We’re tracking 128 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT07309211Recruiting
Durvalumab as maintenance therapy for limited-stage small cell lung cancer
This trial is for people with limited-stage small cell lung cancer who have already finished chemotherapy and radiation, and then started taking Durvalumab (Imfinzi) as a maintenance therapy. The goal is to see if continuing Durvalumab helps keep the cancer from coming back.
JinanAges 18 years+ - NCT07048457RecruitingPhase 2
Surgery for metastatic bladder cancer after initial treatment
This trial tests whether removing the primary bladder tumor and any remaining metastatic spots after initial medication (enfortumab-vedotin) improves outcomes for people with a limited number of metastases (5 or fewer). It is for those whose cancer has responded or stabilized on treatment.
New Haven, ConnecticutAges 18 years+ - NCT07257055RecruitingPhase 2
New drug combo for aggressive mantle cell lymphoma
This trial tests a two-step treatment for people with a fast-growing form of mantle cell lymphoma (MCL). First, you take a daily pill (BTKi) plus an infusion (rituximab), then a newer targeted therapy (glofitamab) to try to make the response last. The goal is to shrink the cancer and keep it away.
Houston, TexasAges 18 years+ - NCT07117136Recruiting
Blinatumomab after standard treatment for B-ALL
This trial is studying how well the drug blinatumomab works for adults with B-cell acute lymphoblastic leukemia (B-ALL) when it is given after the first phase of treatment. It looks at patient data to understand real-world outcomes.
Jacksonville, FloridaAges 18 years+ - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT06095583RecruitingPhase 3
Toripalimab for limited-stage small cell lung cancer after chemoradiation
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
Harbin, HeilongjiangAges 18 years+ - NCT06593431RecruitingPhase 3
Treating limited spread pancreatic cancer with local therapy
This trial tests whether combining local treatments (like radiation or surgery) with standard care can help people with pancreatic cancer that has spread to only a few spots (oligometastatic disease). The goal is to improve outcomes for this specific group of patients.
Camden, New JerseyAges 18 years+ - NCT02416388RecruitingPhase 2/Phase 3
Trial for AML treatments and preventing graft-versus-host disease
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
AmiensAges 18–61 - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT05422690RecruitingPhase 2
Treating bile duct cancer with chemo plus Y-90 radiation
This Phase 2 study tests whether combining chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (durvalumab) with targeted Y-90 radiation can shrink inoperable intrahepatic cholangiocarcinoma tumors. It’s looking for better tumor shrinking and improved cancer control.
Fairfax, VirginiaAges 18 years+ - NCT03046316Recruiting
Local treatment for advanced lung cancer that hasn’t worsened
This trial looks at whether using focused treatments (like surgery or radiation to lung cancer spots) can help people with advanced non-small cell lung cancer whose disease has not progressed after first-line treatment. It’s meant for people who have limited metastatic spots and can safely undergo the local treatment.
Guangzhou, GuagndongAges 18 years+ - NCT03562169RecruitingPhase 3
Ixazomib with your own stem cell transplant for relapsed myeloma
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
AberdeenAges 18 years+ - NCT03865771Recruiting
Sleep study to improve memory in children with focal epilepsy
This study looks at how sleep affects memory in children with certain types of age-related focal epilepsy. It compares them to children hospitalized for non-nerve (non-neurologic) reasons to see whether sleep-related brain patterns relate to learning and memory.
NancyAges 6–13 - NCT04378647RecruitingPhase 2
Brentuximab before transplant for relapsed CD30 Hodgkin lymphoma
This trial studies whether brentuximab vedotin given in the “second-line” setting can help people with relapsed or hard-to-treat classic Hodgkin lymphoma get ready for an autologous (your own cells) stem cell transplant. It’s specifically for tumors that test positive for CD30, and it checks safety and how well treatment works before transplant.
Barcelona, BarceolnaAges 18–65 - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT04628026RecruitingPhase 3
Venetoclax plus chemotherapy for new AML or high-risk MDS
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
InnsbruckAges 18–75 - NCT06796543Recruiting
Radiation for young patients with sarcoma that has spread
This trial tests whether targeted radiation can help children and young adults with sarcoma that has spread to a few spots in the body. It's for those who are newly diagnosed (Stratum A) or whose sarcoma has come back or worsened (Stratum B).
Washington D.C., District of ColumbiaAges Up to 39 years - NCT05334693RecruitingPhase 1/Phase 2
Donor immune cells to help prevent AML return after treatment
This study tests an “immune cell therapy” made from a family donor to help children and young adults with AML stay in remission after chemotherapy. It may help reduce the chance that AML comes back, but eligibility depends on remission status, donor suitability, and avoiding certain infections or liver issues.
Minsk, Minsk OblastAges 6 months–21 years - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
New Brunswick, New JerseyAges 18 years+ - NCT05431764RecruitingPhase 2
PD-1 treatment plus radiation for limited metastatic nasopharyngeal cancer
This Phase 2 trial tests adding a PD-1 “immunotherapy” medicine (a type of cancer-fighting antibody) along with stereotactic body radiotherapy (very focused radiation) to treat nasopharyngeal cancer that has spread to only a few places. It may help shrink remaining visible spots after initial local radiation and see whether this “consolidation” approach improves control of the cancer.
Guangzhou, GuangdongAges 18–70 - NCT05464719RecruitingPhase 2
Loncastuximab for lymphoma patients in partial remission after CAR T
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
Houston, TexasAges 18 years+ - NCT05560113Recruiting
Study uses brain stimulation to disrupt fear memory in PTSD
This study tests a brain stimulation approach to affect how fear memories “stick” after they are formed. If you have PTSD, it may help reduce fear-related learning, but you must meet several safety and health criteria.
Atlanta, GeorgiaAges 18–65
Hear when a new Consolidation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for consolidation?
- Yes. Clin2 currently lists 128 recruiting consolidation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a consolidation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a consolidation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.